Tag: Biosimilars
Biocon Biologics receives European Commission approval for YESAFILI biosimilar Aflibercept
Aflibercept had EU brand sales of approximately $1.8B for the 12 months ending December 31, 2022, according to IQVIA
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Continuing to expand its global footprint, the company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023
India’s biosimilars industry staring at plethora of opportunities
Between now and 2030, biologic products worth US $170 billion will lose patent protection globally, writes Dr Cyrus Karkaria, President – Biotechnology, Lupin Limited
Inflation law drives biologic drugs to outpace small molecules in venture...
According to GlobalData’s Pharma Intelligence Center Deals database, the US biotechs saw 48% or $1.1 billion more in innovator drug venture financing, reaching a total deal value of $3.2 billion in 2023
BioVoice eMagazine June 2023 | Issue 6 | Volume 4
This edition tracks the latest scenario in Indian CRO industry and analyzes whether India can become a hotspot for clinical trials. Key highlights include Expert Insights by Dr Cyrus Karkaria, President- Biotechnology, Lupin and Zoya Brar, Founder, CORE Diagnostics.
Biocon revenue up 59% at Rs 3,929 crore in Q4FY23
The company's revenue in biosimilars is up 114%; research services up 31% and EBITDA at Rs 1,152 crore up 75%
Biocon Biologics’ new mAbs facility receives EU GMP certification for bBevacizumab
This approval reflects Biocon Biologics’ compliance with the highest international regulatory standards and enables the company to continue addressing the needs of patients
Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...
The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period
EU officially allows interchangeability of biosimilars
While interchangeable use of biosimilars is already practiced in many Member States, this joint position harmonizes the EU approach
Lupin & DKSH sign an exclusive licensing & supply agreement to...
According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved